TREAT-GNB

TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation.

Study Design & Objectives

Adaptive platform trial
• Multi-arm randomised trial with a personalisable
randomisation list of antibiotic options (Personalised
RAndomised Controlled Trial [PRACTical] design)

Objectives
1. Identify optimal antibiotic treatment options for severe Gramnegative
bacterial infections
2. Identify adjunctive treatment options for severe Gramnegative
bacilli infections

Enrolment, Sample Size and Sites

The sample size target for Asia is 600 patients from 10 sites and the Singapore sites' target is 120 patients.